NCT03254927 - A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 27, 2018

Primary Completion Date

September 16, 2020

Study Completion Date

December 16, 2020

Conditions

Advanced Head and Neck Squamous Cell Carcinoma

Interventions

DRUG

CDX-3379 and cetuximab

Dose: 12 mg/kg CDX-3379 once every 3 weeks in combination with 400 mg/m2 cetuximab on the first day followed by weekly doses of 250 mg/m2 cetuximab.

Trial Locations (10)

UPMC Hillman Cancer Center, Pittsburgh

University of Pennsylvania Hospital, Abramson Cancer Center, Philadelphia

Medical University of South Carolina, Charleston

Emory University Winship Cancer Institute, Atlanta

Vanderbilt University Medical Center, Nashville

University of Cincinnati, Cincinnati

Rush University Medical center, Chicago

Washington University School of Medicine, St Louis

The University of Arizona Cancer Center, Tucson

Yale Cancer Center, New Haven